Neurotech International Limited (ASX:NTI)
0.0150
-0.0020 (-11.76%)
Aug 5, 2026, 3:59 PM AEST
Neurotech International Revenue
Neurotech International had revenue of 4.74M AUD in the half year ending December 31, 2025, with 47.68% growth. This brings the company's revenue in the last twelve months to 7.07M, up 8,687.82% year-over-year. In the fiscal year ending June 30, 2025, Neurotech International had annual revenue of 2.44M, down -23.07%.
Revenue (ttm)
7.07M
Revenue Growth
+8,687.82%
P/S Ratio
2.79
Revenue / Employee
n/a
Employees
n/a
Market Cap
19.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 2.44M | -732.95K | -23.07% |
| Jun 30, 2024 | 3.18M | 1.98M | 166.00% |
| Jun 30, 2023 | 1.19M | 586.87K | 96.59% |
| Jun 30, 2022 | 607.62K | 401.25K | 194.44% |
| Jun 30, 2021 | 206.37K | 126.03K | 156.86% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Immuron | 7.48M |
| Imugene | 3.94M |
| Noxopharm | 3.40M |
| Proteomics International Laboratories | 3.21M |
| Argenica Therapeutics | 1.01M |
| ReNerve | 333.21K |
| NeuroScientific Biopharmaceuticals | 317.91K |